In-Vitro Toxicology Testing Market

In-Vitro Toxicology Testing Market Size (2022 to 2027)

The size of the global in-vitro toxicology testing market is expected to reach USD 40768 Million by 2027 from USD 21025 Million in 2022, growing at a CAGR of 14.16% from 2022 to 2027.

MARKET DRIVERS:

The growing number of technological advancements, rising research & development in cell culture, and growing demand for in-vitro toxicology tests over conventional in-vivo tests are majorly promoting the global in-vitro toxicology testing market growth.

Recently, regulatory agencies' validation and acceptance of in vitro toxicology testing methods are increasing at a lucrative rate, boosting the market. In several countries, government regulations mandate that animal geno-toxicology testing be performed before marketing the products for certain consumer items, genetically modified foods, vaccines, devices, drugs, industrial chemicals, and pesticides. Furthermore, technological advancements to replace animals for toxicological testing have spurred in vitro testing models. In addition, increasing awareness of toxicity testing studies, expanding health consciousness amongst individuals, and improving economic status in emerging nations, the existence of favorable regulatory authorities for toxicology testing using in-vitro tests drives the market's growth during the forecast period.

MARKET RESTRAINTS:

However, scarcity of in-vitro models to detect immunostimulants & autoimmunity, lack of predictive ability of in vitro testing over in vivo testing, technological advancements limiting the use & decreasing adoption rate are the significant factors restraining the growth of the in-vitro toxicology testing market. In addition, strict government regulations for the in vitro toxicology testing market are anticipated to limit market growth. Furthermore, the inability of in vitro models to regulate immune stimulation and autoimmunity is also expected to be a significant constraint for the global in-vitro toxicology testing market. Furthermore, there is a requirement for skilled professionals, such as researchers and technicians, to perform experiments. Therefore, a lack of knowledge about these technologies and inadequate staff are expected to slow the market down.

REPORT COVERAGE:

This market research report on the global in-vitro toxicology testing market has been segmented and sub-segmented based on the product, type, toxicity endpoints and tests, method, technology, industry, and region.

In-Vitro Toxicology Testing Market – By Product:

• Assays
• Reagents & Labware
• Services
• Growth Hormone Therapy

Based on the product, the assay segment is estimated to command the largest share of the global in-vitro toxicology testing market during the forecast period. This segment is strongly driven by an increasing number of in-vitro tests being performed worldwide, which leads to the recurrent purchase of reagents and other labware.

In-Vitro Toxicology Testing Market – By Type:

• ADME (Absorption, Distribution, Metabolism, and Excretion)
• Dose
• Toxic Substance

Based on the type, the ADME segment is predicted to stand top in leading max shares in the market during the forecast period due to a growing number of early stages in vitro ADME examining tests in preventing failure.

In-Vitro Toxicology Testing Market – By Toxicity Endpoints & Tests:

• Systemic Toxicity
• Dermal Toxicity
• Carcinogenicity
• Ocular Toxicity
• Skin Sensitization & Irritation
• Genotoxicity
• Neurotoxicity
• Organ Toxicity
• Other Toxicity Endpoints & Tests

Based on toxicity endpoints & tests, the systemic toxicity segment is estimated to command the largest share of the global in-vitro toxicology testing market as multiple organ development with assumed blood flow for assessing systemic toxicity drives the segment growth.

The dermal toxicity segment is next in line with a considerable growth rate throughout the forecast period. Dermal toxicology is simple, easy, reliable, and cost-effective. Moreover, advancement related to dermal toxicity and risk assessment tools is projected to surge the segment growth globally.

In-Vitro Toxicology Testing Market – By Technology:

• OMICS Technologies
• Cell Culture Technology
• High-Throughput Technologies
• Molecular Imaging Technologies 

The cell culture technology segment is projected to dominate the market globally based on technology. It is an excellent model for screening toxic effects as it offers consistent samples and reproducible results. Moreover, it supports the tissue-specific function, which urges cell proliferation.

However, the OMICS technologies segment is projected to have the highest CAGR during the forecast period as it provides personalized toxicology data, understanding the toxicity of nano-sized materials.

In-Vitro Toxicology Testing Market – By Method:

• In-Silico Methods
• Biochemical Assays
• Cellular Assays
• Ex-Vivo Models

In-Vitro Toxicology Testing Market – By Industry:

• Cosmetics and Household Products
• Diagnostics
• Pharmaceuticals
• Food Industry
• Chemicals

Based on industry, the cosmetics & household products industry accounted for the largest market share of the global in-vitro toxicology testing market by industry in 2021.

However, the pharmaceutical segment is expected to dominate the market during the forecast period as the rise influences this segment in support of the government. In addition, launching innovative drugs with advanced technologies mainly surges the demand for this segment.

The chemical industry is expected to witness lucrative growth over the forecast period due to continuous toxicity profiling and safety assessment advancements.

In-Vitro Toxicology Testing Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Globally, the In-Vitro Toxicology Testing Market in Europe is estimated to account for 32.5% of the global in-vitro toxicology testing market in 2019. and Germany is anticipated to dominate and have the largest share in this region. France is expected to grow with the highest CAGR over the forecast period.

The In-Vitro Toxicology Testing Market in North America is anticipated to dominate the global IVTT market over the forecast period. Support from government regulations and the adoption of technological advancements are propelling the market's demand. The U.S. is leading the market in this region because of genetics and genetic screening approaches and the emergence of a new 3D cell culture approach.

The In-Vitro Toxicology Testing Market in Asia-Pacific is expected to grow at the highest CAGR of 16.10% during the forecast period. The growth is attributed to the emergence of CROs for outsourcing toxicology-relevant research projects and increasing consumer awareness of product safety.

The In-Vitro Toxicology Testing Market in Latin America is expected to have a commendable share in the IVTT. With an increasingly aging population, research and development investments influence cell culture research. Brazil is leading the IVTT market.

The In-Vitro Toxicology Testing Market in the Middle East & Africa region is expected to have minimal growth in the IVTT market due to the demand for advanced technologies and the appearance of various analytical methods over bioinformatics and biotechnology.

KEY MARKET PARTICIPANTS:

Noteworthy companies operating in the global in-vitro toxicology testing market include Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.

RECENT MARKET HAPPENINGS:

• In February 2020, Catalent Inc. announced its wholly-owned subsidiary, Catalent Pharma Solutions. 
• In March 2018, BioIVT announced the acquisition of Ascendance Biotechnology, Inc.
• In December 2016, Ascendance Biotechnology Inc., a leader in the commercialization of In-Vitro cell-based and stem-related laboratory products, announced the agreement with GE healthcare providing a right to manufacture, market, and sell the GE Healthcare Cytivaof human stem cell-derived and heart muscle cells used for evaluating potential cardiotoxicity. 
• In December 2015, BioTime Inc. regenerative medicine company and Hepregen Corporation announced the formation of Ascendance Biotechnology Inc. Ascendance combines Hepregen’s application–directed, cellular micro-patterning drug and chemical screening technologies with BioTime’s ESI BIO research products and proprietary stem cell-based technologies. 
• In January 2012, Sigma-Aldrich, a leading Life Science and High Technology company, announced that it had completed its acquisition of Bio reliance Holdings Inc., a leading provider of biopharmaceutical testing services, from Avista Capital Partners.